Bloomberg -- Novartis AG’s effort to add $1 billion in sales to its bone-repair drug Zomenta with an added approval in breast cancer stalled today when the treatment failed to stop tumors from returning in a study. Zometa combined with standard treatments didn’t slow the disease or prolong life, according to a 3,360-patient study presented today at the San Antonio Breast Cancer Symposium in Texas. An earlier, smaller study showed Zometa users were 32 percent less likely to have their cancer recur after five years.
